Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

SGLT2-Inhibitors - significant role in Heart Failure treatment
  • Home
  • /
  • SGLT2-Inhibitors - significant role in Heart Failure treatment
  1. Home /
  2. Archives /
  3. Vol. 71 (2024) /
  4. Medical Sciences

SGLT2-Inhibitors - significant role in Heart Failure treatment

Authors

  • Karol Wielgus Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0007-5315-8556
  • Piotr Bator Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0009-3300-0078
  • Maria Pawłowska Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0005-7947-9134
  • Karol Magiera Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0004-8621-9755
  • Krystian Rachwał Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0002-2527-6110
  • Maria Antos Collegium Medicum, Jan Kochanowski University, IX Wieków Kielc 19A, 25-317 Kielce, Poland https://orcid.org/0009-0000-6085-3652
  • Jan Ramian Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0002-1956-241X
  • Grzegorz Łyko Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland https://orcid.org/0009-0005-8118-6779

DOI:

https://doi.org/10.12775/JEHS.2024.71.49418

Keywords

Heart failure, SGLT2 inhibitors, LVEF

Abstract

Heart failure (HF), which has a high morbidity and mortality rate, is nevertheless a common and crippling ailment, especially in older populations. The complicated pathophysiology of heart failure (HF), which includes oxidative stress, endothelial dysfunction, fibrosis, and inflammation, is frequently not sufficiently treated despite advances in medication. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become a key treatment for HF in patients with varying left ventricular ejection fractions (LVEF). SGLT2 inhibitors have been shown in recent clinical trials to considerably lower hospitalization rates for heart failure, cardiovascular mortality, and all-cause mortality. The mechanisms of SGLT2 inhibitors, such as better ventricular loading, increased heart metabolic efficiency, and decreased inflammation and necrosis, are covered in this review. Additionally, we provide an overview of four important clinical trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER—highlighting their effectiveness in lowering unfavourable cardiovascular outcomes for patients with heart failure who have preserved (HFpEF), slightly reduced (HFmrEF), or reduced (HFrEF). The results validate the need for SGLT2 inhibitors in all-inclusive HF treatment plans by highlighting their adaptability and safety in a range of clinical contexts.

References

Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022). Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Research and Clinical Practice, 188, 109927. https://doi.org/10.1016/j.diabres.2022.109927

Cavallari, I., Crispino, S.P., Segreti, A. et al. Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure. Am J Cardiovasc Drugs 23, 609–621 (2023). https://doi.org/10.1007/s40256-023-00601-9

Talha, K. M., Anker, S. D., & Butler, J. (2023). SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. International Journal of Heart Failure, 5(2), 82-90. doi: 10.36628/ijhf.2022.0030

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. DOI: 10.1056/NEJMoa1504720

McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. DOI: 10.1056/NEJMoa1911303

Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353–1368. doi:10.1001/jama.2020.1906

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. DOI: 10.1056/NEJMoa2107038

Solomon SD, McMurray JJ, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–1098. DOI: 10.1056/NEJMoa2206286

Girerd N, Zannad F. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. J Intern Med. 2023; 293: 550–558. https://doi.org/10.1111/joim.13620

Downloads

  • PDF

Published

2024-05-22

How to Cite

1.
WIELGUS, Karol, BATOR, Piotr, PAWŁOWSKA, Maria, MAGIERA, Karol, RACHWAŁ, Krystian, ANTOS, Maria, RAMIAN, Jan and ŁYKO, Grzegorz. SGLT2-Inhibitors - significant role in Heart Failure treatment. Journal of Education, Health and Sport. Online. 22 May 2024. Vol. 71, p. 49418. [Accessed 6 July 2025]. DOI 10.12775/JEHS.2024.71.49418.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 71 (2024)

Section

Medical Sciences

License

Copyright (c) 2024 Karol Wielgus, Piotr Bator, Maria Pawłowska, Karol Magiera, Krystian Rachwał, Maria Antos, Jan Ramian, Grzegorz Łyko

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 379
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Heart failure, SGLT2 inhibitors, LVEF
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop